Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1

Shuqin Wang; Xue Li; Weizhe Xu; Jing Gao; Yin Wang; Xiaoyuan Jia; Gongchu Li; Qiuwei Pan; Kan Chen

doi:10.3390/ijms232416063

Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1

Shuqin Wang
, Xue Li
, Weizhe Xu
, Jing Gao
, Yin Wang
, Xiaoyuan Jia
, Gongchu Li
, Qiuwei Pan
, Kan Chen^*

^*Corresponding author for this work

Gastroenterology & Hepatology

Zhejiang Sci-Tech University

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

35 Downloads (Pure)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.

Original language	English
Article number	16063
Journal	International Journal of Molecular Sciences
Volume	23
Issue number	24
DOIs	https://doi.org/10.3390/ijms232416063
Publication status	Published - 16 Dec 2022

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation of China (No. 81972281), and Natural Science Foundation of Zhejiang Province (No. LGF22C010005).

Publisher Copyright:
© 2022 by the authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms232416063Licence: CC BY

Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1Final published version, 990 KBLicence: CC BY

Cite this

@article{b4a1b37ab35b423ca8dd3a173a3186dd,

title = "Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1",

abstract = "Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.",

author = "Shuqin Wang and Xue Li and Weizhe Xu and Jing Gao and Yin Wang and Xiaoyuan Jia and Gongchu Li and Qiuwei Pan and Kan Chen",

note = "Funding Information: This work was supported by the National Natural Science Foundation of China (No. 81972281), and Natural Science Foundation of Zhejiang Province (No. LGF22C010005). Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = dec,

day = "16",

doi = "10.3390/ijms232416063",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "24",

}

TY - JOUR

T1 - Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1

AU - Wang, Shuqin

AU - Li, Xue

AU - Xu, Weizhe

AU - Gao, Jing

AU - Wang, Yin

AU - Jia, Xiaoyuan

AU - Li, Gongchu

AU - Pan, Qiuwei

AU - Chen, Kan

N1 - Funding Information: This work was supported by the National Natural Science Foundation of China (No. 81972281), and Natural Science Foundation of Zhejiang Province (No. LGF22C010005). Publisher Copyright: © 2022 by the authors.

PY - 2022/12/16

Y1 - 2022/12/16

N2 - Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.

AB - Nonalcoholic fatty liver disease (NAFLD) is recognized as a metabolic disease characterized by hepatic steatosis. Despite the growing burden of NAFLD, approved pharmacological treatment is lacking. As an inhibitor of androgen receptor (AR), EPI-001 is being explored for the treatment of prostate cancer. This study aimed to investigate the potential of EPI-001 for treating NAFLD in free fatty acids (FFAs)-induced human hepatic cells and high-fat-high-sugar (HFHS)-feeding mice. Our results showed that EPI-001 reduced lipid accumulation in hepatic cells and ameliorated hepatic steatosis in mouse livers. Further exploration suggested that the effect of EPI-001 was associated with CYP2E1-mediated reduction of reactive oxygen species (ROS). This provides encouraging evidence for further studies on EPI-001 therapy for NAFLD.

UR - https://www.scopus.com/pages/publications/85144713137

U2 - 10.3390/ijms232416063

DO - 10.3390/ijms232416063

M3 - Article

C2 - 36555703

AN - SCOPUS:85144713137

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 24

M1 - 16063

ER -

Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this